Home Journal Club	FAQ My Amedeo About Tranquillis Services	Flying Publisher
	Books, Journals, Podcasts, Weekly Updates, by Amedeo

Prostate Cancer

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 127 articles: HTML format Text format

Single Articles

March 2010
1. GALLAGHER DJ , Gaudet MM, Pal P, Kirchhoff T, et al
   Germline BRCA Mutations Denote a Clinicopathologic Subset of Prostate Cancer.
   Clin Cancer Res. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   
2. SCIARRA A , Panebianco V, Ciccariello M, Salciccia S, et al
   Value of Magnetic Resonance Spectroscopy Imaging and Dynamic Contrast-Enhanced Imaging for Detecting Prostate Cancer Foci in Men With Prior Negative Biopsy.
   Clin Cancer Res. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   February 2010
3. MINNER S , Jessen B, Stiedenroth L, Burandt E, et al
   Low Level Her2 Overexpression Is Associated with Rapid Tumor Cell Proliferation and Poor Prognosis in Prostate Cancer.
   Clin Cancer Res. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   
4. WALSH P
   Is High-Grade Prostate Cancer Easier to Find in Smaller Prostates Because There Is More High-Grade Disease to Find? - Letter.
   Clin Cancer Res. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   
5. PRESTI J JR
   Is High-Grade Prostate Cancer Easier to Find in Smaller Prostates Because There Is More High-Grade Disease to Find? Response.
   Clin Cancer Res. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   
6. RICE KR , Chen Y, Ali A, Whitman EJ, et al
   Evaluation of the ETS-Related Gene mRNA in Urine for the Detection of Prostate Cancer.
   Clin Cancer Res. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   
7. EFSTATHIOU E , Logothetis CJ
   A New Therapy Paradigm for Prostate Cancer Founded on Clinical Observations.
   Clin Cancer Res. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   
8. HAMMARSTEN P , Karalija A, Josefsson A, Rudolfsson SH, et al
   Low Levels of Phosphorylated Epidermal Growth Factor Receptor in Nonmalignant and Malignant Prostate Tissue Predict Favorable Outcome in Prostate Cancer Patients.
   Clin Cancer Res. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   December 2009
9. PARIS PL , Weinberg V, Albo G, Roy R, et al
   A Group of Genome-Based Biomarkers That Add to a Kattan Nomogram for Predicting Progression in Men with High-Risk Prostate Cancer.
   Clin Cancer Res. 2009.
   PubMed     Text format     Related articles    Abstract available
   
   
   
10. EL GAMMAL AT , Bruchmann M, Zustin J, Isbarn H, et al
    Chromosome 8p Deletions and 8q Gains are Associated with Tumor Progression and Poor Prognosis in Prostate Cancer.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
11. KIMURA T , Kuwata T, Ashimine S, Yamazaki M, et al
    Targeting of Bone-Derived Insulin-Like Growth Factor-II by a Human Neutralizing Antibody Suppresses the Growth of Prostate Cancer Cells in a Human Bone Environment.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
12. ARMSTRONG AJ , Garrett-Mayer E, de Wit R, Tannock I, et al
    Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
13. TITUS MA , Tan JA, Gregory CW, Ford OH, et al
    14-3-3{eta} Amplifies Androgen Receptor Actions in Prostate Cancer.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
14. SPRENGER CC , Haugk K, Sun S, Coleman I, et al
    Transforming Growth Factor-{beta}-Stimulated Clone-22 Is an Androgen-Regulated Gene That Enhances Apoptosis in Prostate Cancer following Insulin-Like Growth Factor-I Receptor Inhibition.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    November 2009
15. MAKAROV DV , Isharwal S, Sokoll LJ, Landis P, et al
    Pro-Prostate-Specific Antigen Measurements in Serum and Tissue Are Associated with Treatment Necessity among Men Enrolled in Expectant Management for Prostate Cancer.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
16. YU EY , Wilding G, Posadas E, Gross M, et al
    Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
17. CHANDA D , Isayeva T, Kumar S, Hensel JA, et al
    Therapeutic Potential of Adult Bone Marrow-Derived Mesenchymal Stem Cells in Prostate Cancer Bone Metastasis.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
18. LUBAROFF DM , Konety BR, Link B, Gerstbrein J, et al
    Phase I Clinical Trial of an Adenovirus/Prostate-Specific Antigen Vaccine for Prostate Cancer: Safety and Immunologic Results.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
19. TAPLIN ME , Regan MM, Ko YJ, Bubley GJ, et al
    Phase II Study of Androgen Synthesis Inhibition with Ketoconazole, Hydrocortisone, and Dutasteride in Asymptomatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    October 2009
20. BROWN DA , Lindmark F, Stattin P, Balter K, et al
    Macrophage Inhibitory Cytokine 1: A New Prognostic Marker in Prostate Cancer.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
21. HERMANS KG , Boormans JL, Gasi D, van Leenders GJ, et al
    Overexpression of Prostate-Specific TMPRSS2(exon 0)-ERG Fusion Transcripts Corresponds with Favorable Prognosis of Prostate Cancer.
    Clin Cancer Res. 2009;15:6398-403.
    PubMed     Text format     Related articles    Abstract available
    
    
    
22. ILJIN K , Ketola K, Vainio P, Halonen P, et al
    High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth.
    Clin Cancer Res. 2009;15:6070-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    September 2009
23. ARREDOUANI MS , Lu B, Bhasin M, Eljanne M, et al
    Identification of the Transcription Factor Single-Minded Homologue 2 as a Potential Biomarker and Immunotherapy Target in Prostate Cancer.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    August 2009
24. BOWER JE , Ganz PA, Lin Tao M, Hu W, et al
    Inflammatory Biomarkers and Fatigue during Radiation Therapy for Breast and Prostate Cancer.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
25. HAKKARAINEN T , Rajecki M, Sarparanta M, Tenhunen M, et al
    Targeted Radiotherapy for Prostate Cancer with an Oncolytic Adenovirus Coding for Human Sodium Iodide Symporter.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
26. POLLACK A , Bae K, Khor LY, Al-Saleem T, et al
    The Importance of Protein Kinase A in Prostate Cancer: Relationship to Patient Outcome in Radiation Therapy Oncology Group Trial 92-02.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
27. COMSTOCK CE , Augello MA, Benito RP, Karch J, et al
    Cyclin D1 Splice Variants: Polymorphism, Risk, and Isoform-Specific Regulation in Prostate Cancer.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
28. CHRISTENSEN E , Pintilie M, Evans KR, Lenarduzzi M, et al
    Longitudinal Cytokine Expression during IMRT for Prostate Cancer and Acute Treatment Toxicity.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
29. TSAI CH , Lin FM, Yang YC, Lee MT, et al
    Herbal Extract of Wedelia chinensis Attenuates Androgen Receptor Activity and Orthotopic Growth of Prostate Cancer in Nude Mice.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
30. LEE CY , Rennie PS, Jia WW
    MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells.
    Clin Cancer Res. 2009;15:5126-35.
    PubMed     Text format     Related articles    Abstract available
    
    
    
31. JAIN A , McKnight DA, Fisher LW, Humphreys EB, et al
    Small integrin-binding proteins as serum markers for prostate cancer detection.
    Clin Cancer Res. 2009;15:5199-207.
    PubMed     Text format     Related articles    Abstract available
    
    
    
32. CHUN JY , Nadiminty N, Dutt S, Lou W, et al
    Interleukin-6 regulates androgen synthesis in prostate cancer cells.
    Clin Cancer Res. 2009;15:4815-22.
    PubMed     Text format     Related articles    Abstract available
    
    
    
33. KNUDSEN KE , Scher HI
    Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer.
    Clin Cancer Res. 2009;15:4792-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
34. SARKER D , Reid AH, Yap TA, de Bono JS, et al
    Targeting the PI3K/AKT pathway for the treatment of prostate cancer.
    Clin Cancer Res. 2009;15:4799-805.
    PubMed     Text format     Related articles    Abstract available
    
    
    July 2009
35. FONTANA A , Galli L, Fioravanti A, Orlandi P, et al
    Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refractory Prostate Cancer.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
36. STAN SD , Singh SV
    Transcriptional Repression and Inhibition of Nuclear Translocation of Androgen Receptor by Diallyl Trisulfide in Human Prostate Cancer Cells.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
37. ELLIOTT CS , Shinghal R, Presti JC Jr
    The Influence of Prostate Volume on Prostate-Specific Antigen Performance: Implications for the Prostate Cancer Prevention Trial Outcomes.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
38. MOSQUERA JM , Mehra R, Regan MM, Perner S, et al
    Prevalence of TMPRSS2-ERG Fusion Prostate Cancer among Men Undergoing Prostate Biopsy in the United States.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    June 2009
39. RUSSO AL , Jedlicka K, Wernick M, McNally D, et al
    Urine Analysis and Protein Networking Identify Met as a Marker of Metastatic Prostate Cancer.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
40. DAKHOVA O , Ozen M, Creighton CJ, Li R, et al
    Global Gene Expression Analysis of Reactive Stroma in Prostate Cancer.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
41. CHUA CW , Chiu YT, Yuen HF, Chan KW, et al
    Suppression of Androgen-Independent Prostate Cancer Cell Aggressiveness by FTY720: Validating Runx2 as a Potential Antimetastatic Drug Screening Platform.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    May 2009
42. ATTAR RM , Takimoto CH, Gottardis MM
    Castration-resistant prostate cancer: locking up the molecular escape routes.
    Clin Cancer Res. 2009;15:3251-5.
    PubMed     Text format     Related articles    Abstract available
    
    
    
43. TATAROV O , Mitchell TJ, Seywright M, Leung HY, et al
    SRC family kinase activity is up-regulated in hormone-refractory prostate cancer.
    Clin Cancer Res. 2009;15:3540-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
44. ZHANG Q , Helfand BT, Jang TL, Zhu LJ, et al
    Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy.
    Clin Cancer Res. 2009;15:3557-67.
    PubMed     Text format     Related articles    Abstract available
    
    
    
45. SHUKLA-DAVE A , Hricak H, Ishill N, Moskowitz CS, et al
    Prediction of Prostate Cancer Recurrence Using Magnetic Resonance Imaging and Molecular Profiles.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
46. LI R , Dai H, Wheeler TM, Sayeeduddin M, et al
    Prognostic Value of Akt-1 in Human Prostate Cancer: A Computerized Quantitative Assessment with Quantum Dot Technology.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
47. THIRKETTLE HJ , Girling J, Warren AY, Mills IG, et al
    LYRIC/AEG-1 is targeted to different subcellular compartments by ubiquitinylation and intrinsic nuclear localization signals.
    Clin Cancer Res. 2009;15:3003-13.
    PubMed     Text format     Related articles    Abstract available
    
    
    
48. CHUNG EJ , Brown AP, Asano H, Mandler M, et al
    In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase.
    Clin Cancer Res. 2009;15:3050-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    April 2009
49. DI CARLO E , D'Antuono T, Pompa P, Giuliani R, et al
    The Lack of Epithelial Interleukin-7 and BAFF/BLyS Gene Expression in Prostate Cancer as a Possible Mechanism of Tumor Escape from Immunosurveillance.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
50. QIAN DZ , Huang CY, O'Brien CA, Coleman IM, et al
    Prostate Cancer-Associated Gene Expression Alterations Determined from Needle Biopsies.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
51. FITZGERALD LM , Kwon EM, Koopmeiners JS, Salinas CA, et al
    Analysis of Recently Identified Prostate Cancer Susceptibility Loci in a Population-based Study: Associations with Family History and Clinical Features.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
52. PENNEY KL , Salinas CA, Pomerantz M, Schumacher FR, et al
    Evaluation of 8q24 and 17q Risk Loci and Prostate Cancer Mortality.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
53. LIU G , Kelly WK, Wilding G, Leopold L, et al
    An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate Cancer.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
54. KHATRI A , Husaini Y, Ow K, Chapman J, et al
    Cytosine deaminase-uracil phosphoribosyltransferase and interleukin (IL)-12 and IL-18: a multimodal anticancer interface marked by specific modulation in serum cytokines.
    Clin Cancer Res. 2009;15:2323-34.
    PubMed     Text format     Related articles    Abstract available
    
    
    March 2009
55. FRADET V , Cheng I, Casey G, Witte JS, et al
    Dietary Omega-3 Fatty Acids, Cyclooxygenase-2 Genetic Variation, and Aggressive Prostate Cancer Risk.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
56. LEVERSHA MA , Han J, Asgari Z, Danila DC, et al
    Fluorescence In situ Hybridization Analysis of Circulating Tumor Cells in Metastatic Prostate Cancer.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
57. CHAVIN G , Sheinin Y, Crispen PL, Boorjian SA, et al
    Expression of Immunosuppresive B7-H3 Ligand by Hormone-Treated Prostate Cancer Tumors and Metastases.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
58. ADHAMI VM , Siddiqui IA, Sarfaraz S, Khwaja SI, et al
    Effective Prostate Cancer Chemopreventive Intervention with Green Tea Polyphenols in the TRAMP Model Depends on the Stage of the Disease.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
59. IBARAGI S , Yoshioka N, Li S, Hu MG, et al
    Neamine Inhibits Prostate Cancer Growth by Suppressing Angiogenin-Mediated rRNA Transcription.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
60. CHEN FH , Chiang CS, Wang CC, Tsai CS, et al
    Radiotherapy decreases vascular density and causes hypoxia with macrophage aggregation in TRAMP-C1 prostate tumors.
    Clin Cancer Res. 2009;15:1721-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
61. GANAPATHY M , Ghosh R, Jianping X, Zhang X, et al
    Involvement of FLIP in 2-methoxyestradiol-induced tumor regression in transgenic adenocarcinoma of mouse prostate model.
    Clin Cancer Res. 2009;15:1601-11.
    PubMed     Text format     Related articles    Abstract available
    
    
    
62. MIROCHNIK Y , Aurora A, Schulze-Hoepfner FT, Deabes A, et al
    Short pigment epithelial-derived factor-derived peptide inhibits angiogenesis and tumor growth.
    Clin Cancer Res. 2009;15:1655-63.
    PubMed     Text format     Related articles    Abstract available
    
    
    February 2009
63. SCHAYEK H , Haugk K, Sun S, True LD, et al
    Tumor Suppressor BRCA1 Is Expressed in Prostate Cancer and Controls Insulin-like Growth Factor I Receptor (IGF-IR) Gene Transcription in an Androgen Receptor-Dependent Manner.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
64. NAM RK , Zhang WW, Trachtenberg J, Seth A, et al
    Utility of Incorporating Genetic Variants for the Early Detection of Prostate Cancer.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
65. GLINSKY GV
    Quantitative analysis of circulating tumor cells as a survival predictor in metastatic castration-resistant prostate cancer: missing parts in a superb study.
    Clin Cancer Res. 2009;15:1504.
    PubMed     Text format     Related articles   
    
    
    
66. SORENSEN KD , Wild PJ, Mortezavi A, Adolf K, et al
    Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy.
    Clin Cancer Res. 2009;15:1400-10.
    PubMed     Text format     Related articles    Abstract available
    
    
    
67. DARNEL AD , Behmoaram E, Vollmer RT, Corcos J, et al
    Fascin regulates prostate cancer cell invasion and is associated with metastasis and biochemical failure in prostate cancer.
    Clin Cancer Res. 2009;15:1376-83.
    PubMed     Text format     Related articles    Abstract available
    
    
    
68. KING JW , Thomas S, Corsi F, Gao L, et al
    IL15 can reverse the unresponsiveness of Wilms' tumor antigen-specific CTL in patients with prostate cancer.
    Clin Cancer Res. 2009;15:1145-54.
    PubMed     Text format     Related articles    Abstract available
    
    
    
69. AGALLIU I , Gern R, Leanza S, Burk RD, et al
    Associations of High-Grade Prostate Cancer with BRCA1 and BRCA2 Founder Mutations.
    Clin Cancer Res. 2009;15:1112-20.
    PubMed     Text format     Related articles    Abstract available
    
    
    
70. ZHENG SL , Sun J, Wiklund F, Gao Z, et al
    Genetic variants and family history predict prostate cancer similar to prostate-specific antigen.
    Clin Cancer Res. 2009;15:1105-11.
    PubMed     Text format     Related articles    Abstract available
    
    
    
71. SCHWARZENBACH H , Alix-Panabieres C, Muller I, Letang N, et al
    Cell-free Tumor DNA in Blood Plasma As a Marker for Circulating Tumor Cells in Prostate Cancer.
    Clin Cancer Res. 2009;15:1032-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
72. NI J , Mai T, Pang ST, Haque I, et al
    In vitro and In vivo Anticancer Effects of the Novel Vitamin E Ether Analogue RRR-{alpha}-Tocopheryloxybutyl Sulfonic Acid in Prostate Cancer.
    Clin Cancer Res. 2009;15:898-906.
    PubMed     Text format     Related articles    Abstract available
    
    
    
73. LI Y , Song E, Abbas Rizvi SM, Power CA, et al
    Inhibition of Micrometastatic Prostate Cancer Cell Spread in Animal Models By 213Bilabeled Multiple Targeted {alpha} Radioimmunoconjugates.
    Clin Cancer Res. 2009;15:865-875.
    PubMed     Text format     Related articles    Abstract available
    
    
    
74. BEDOLLA RG , Wang Y, Asuncion A, Chamie K, et al
    Nuclear versus Cytoplasmic Localization of Filamin A in Prostate Cancer: Immunohistochemical Correlation with Metastases.
    Clin Cancer Res. 2009;15:788-796.
    PubMed     Text format     Related articles    Abstract available
    
    
    
75. ZHOU P , Zheng X, Zhang H, Liu Y, et al
    B7 blockade alters the balance between regulatory T cells and tumor-reactive T cells for immunotherapy of cancer.
    Clin Cancer Res. 2009;15:960-70.
    PubMed     Text format     Related articles    Abstract available
    
    
    January 2009
76. MORGAN TM , Lange PH, Porter MP, Lin DW, et al
    Disseminated Tumor Cells in Prostate Cancer Patients after Radical Prostatectomy and without Evidence of Disease Predicts Biochemical Recurrence.
    Clin Cancer Res. 2009;15:677-83.
    PubMed     Text format     Related articles    Abstract available
    
    
    
77. SINGH RP , Raina K, Deep G, Chan D, et al
    Silibinin Suppresses Growth of Human Prostate Carcinoma PC-3 Orthotopic Xenograft via Activation of Extracellular Signal-Regulated Kinase 1/2 and Inhibition of Signal Transducers and Activators of Transcription Signaling.
    Clin Cancer Res. 2009;15:613-621.
    PubMed     Text format     Related articles    Abstract available
    
    
    
78. BIN HAFEEZ B , Adhami VM, Asim M, Siddiqui IA, et al
    Targeted knockdown of notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator.
    Clin Cancer Res. 2009;15:452-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
79. MA J , Waxman DJ
    Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinib.
    Clin Cancer Res. 2009;15:578-88.
    PubMed     Text format     Related articles    Abstract available
    
    
    
80. YIN Y , Ni J, Chen M, Guo Y, et al
    RRR-{alpha}-Vitamin E Succinate Potentiates the Antitumor Effect of Calcitriol in Prostate Cancer without Overt Side Effects.
    Clin Cancer Res. 2009;15:190-200.
    PubMed     Text format     Related articles    Abstract available
    
    
    
81. DONG Y , Chin SF, Blanco E, Bey EA, et al
    Intratumoral Delivery of {beta}-Lapachone via Polymer Implants for Prostate Cancer Therapy.
    Clin Cancer Res. 2009;15:131-139.
    PubMed     Text format     Related articles    Abstract available
    
    
    
82. FROMONT G
    Prediction of cancer relapse after prostatectomy: use the postoperative nomogram.
    Clin Cancer Res. 2009;15:413.
    PubMed     Text format     Related articles   
    
    
    
83. SNOEK R , Cheng H, Margiotti K, Wafa LA, et al
    In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors.
    Clin Cancer Res. 2009;15:39-47.
    PubMed     Text format     Related articles    Abstract available
    
    
    December 2008
84. PATEL MI , Singh J, Niknami M, Kurek C, et al
    Cytosolic Phospholipase A2-{alpha}: A Potential Therapeutic Target for Prostate Cancer.
    Clin Cancer Res. 2008;14:8070-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
85. HEATH EI , Hillman DW, Vaishampayan U, Sheng S, et al
    A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer.
    Clin Cancer Res. 2008;14:7940-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    
86. FLEISCHMANN A , Schlomm T, Huland H, Kollermann J, et al
    Distinct Subcellular Expression Patterns of Neutral Endopeptidase (CD10) in Prostate Cancer Predict Diverging Clinical Courses in Surgically Treated Patients.
    Clin Cancer Res. 2008;14:7838-42.
    PubMed     Text format     Related articles    Abstract available
    
    
    
87. BLUM DL , Koyama T, M'koma AE, Iturregui JM, et al
    Chemokine Markers Predict Biochemical Recurrence of Prostate Cancer following Prostatectomy.
    Clin Cancer Res. 2008;14:7790-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    
88. DAI Y , Liu M, Tang W, Desano J, et al
    Molecularly targeted radiosensitization of human prostate cancer by modulating inhibitor of apoptosis.
    Clin Cancer Res. 2008;14:7701-10.
    PubMed     Text format     Related articles    Abstract available
    
    
    
89. AYALA GE , Dai H, Powell M, Li R, et al
    Cancer-related axonogenesis and neurogenesis in prostate cancer.
    Clin Cancer Res. 2008;14:7593-603.
    PubMed     Text format     Related articles    Abstract available
    
    
    
90. BHATT RS , Bubley GJ
    The challenge of herbal therapies for prostate cancer.
    Clin Cancer Res. 2008;14:7581-2.
    PubMed     Text format     Related articles    Abstract available
    
    
    
91. SINGH RP , Raina K, Sharma G, Agarwal R, et al
    Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice.
    Clin Cancer Res. 2008;14:7773-80.
    PubMed     Text format     Related articles    Abstract available
    
    
    November 2008
92. CASTELLANO G , Malaponte G, Mazzarino MC, Figini M, et al
    Activation of the Osteopontin/Matrix Metalloproteinase-9 Pathway Correlates with Prostate Cancer Progression.
    Clin Cancer Res. 2008;14:7470-7480.
    PubMed     Text format     Related articles    Abstract available
    
    
    
93. GUPTA A , Karakiewicz PI, Roehrborn CG, Lotan Y, et al
    Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer.
    Clin Cancer Res. 2008;14:7385-90.
    PubMed     Text format     Related articles    Abstract available
    
    
    
94. AYALA G , Yan J, Li R, Ding Y, et al
    Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt.
    Clin Cancer Res. 2008;14:7511-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
95. LEYTON JV , Olafsen T, Lepin EJ, Hahm S, et al
    Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors.
    Clin Cancer Res. 2008;14:7488-96.
    PubMed     Text format     Related articles    Abstract available
    
    
    
96. KORTENHORST MS , Zahurak M, Shabbeer S, Kachhap S, et al
    A multiple-loop, double-cube microarray design applied to prostate cancer cell lines with variable sensitivity to histone deacetylase inhibitors.
    Clin Cancer Res. 2008;14:6886-94.
    PubMed     Text format     Related articles    Abstract available
    
    
    
97. SHANKAR S , Ganapathy S, Srivastava RK
    Sulforaphane Enhances the Therapeutic Potential of TRAIL in Prostate Cancer Orthotopic Model through Regulation of Apoptosis, Metastasis, and Angiogenesis.
    Clin Cancer Res. 2008;14:6855-66.
    PubMed     Text format     Related articles    Abstract available
    
    
    October 2008
98. LINDSTROM S , Adami HO, Adolfsson J, Wiklund F, et al
    Y chromosome haplotypes and prostate cancer in sweden.
    Clin Cancer Res. 2008;14:6712-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    
99. ROY R , Louis G, Loughlin KR, Wiederschain D, et al
    Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species.
    Clin Cancer Res. 2008;14:6610-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    
100. DE BONO JS , Scher HI, Montgomery RB, Parker C, et al
     Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.
     Clin Cancer Res. 2008;14:6302-9.
     PubMed     Text format     Related articles    Abstract available
     
     
     
101. ARMSTRONG AJ , Creel P, Turnbull J, Moore C, et al
     A Phase I-II Study of Docetaxel and Atrasentan in Men with Castration-Resistant Metastatic Prostate Cancer.
     Clin Cancer Res. 2008;14:6270-6.
     PubMed     Text format     Related articles    Abstract available
     
     
     
102. SEO SI , Gera L, Zhau HE, Qian WP, et al
     BKM1740, an Acyl-Tyrosine Bisphosphonate Amide Derivative, Inhibits the Bone Metastatic Growth of Human Prostate Cancer Cells by Inducing Apoptosis.
     Clin Cancer Res. 2008;14:6198-206.
     PubMed     Text format     Related articles    Abstract available
     
     
     
103. SHARIFI N , Hurt EM, Thomas SB, Farrar WL, et al
     Effects of manganese superoxide dismutase silencing on androgen receptor function and gene regulation: implications for castration-resistant prostate cancer.
     Clin Cancer Res. 2008;14:6073-80.
     PubMed     Text format     Related articles    Abstract available
     
     
     
104. DAGVADORJ A , Tan SH, Liao Z, Cavalli LR, et al
     Androgen-Regulated and Highly Tumorigenic Human Prostate Cancer Cell Line Established from a Transplantable Primary CWR22 Tumor.
     Clin Cancer Res. 2008;14:6062-72.
     PubMed     Text format     Related articles    Abstract available
     
     
     September 2008
105. XU J , Isaacs SD, Sun J, Li G, et al
     Association of prostate cancer risk variants with clinicopathologic characteristics of the disease.
     Clin Cancer Res. 2008;14:5819-24.
     PubMed     Text format     Related articles    Abstract available
     
     
     
106. NARITA S , So A, Ettinger S, Hayashi N, et al
     GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer.
     Clin Cancer Res. 2008;14:5769-77.
     PubMed     Text format     Related articles    Abstract available
     
     
     
107. CUSSENOT O , Azzouzi AR, Bantsimba-Malanda G, Gaffory C, et al
     Effect of Genetic Variability within 8q24 on Aggressiveness Patterns at Diagnosis and Familial Status of Prostate Cancer.
     Clin Cancer Res. 2008;14:5635-9.
     PubMed     Text format     Related articles    Abstract available
     
     
     
108. GOLOVINE K , Makhov P, Uzzo RG, Shaw T, et al
     Overexpression of the Zinc Uptake Transporter hZIP1 Inhibits Nuclear Factor-{kappa}B and Reduces the Malignant Potential of Prostate Cancer Cells In vitro and In vivo.
     Clin Cancer Res. 2008;14:5376-84.
     PubMed     Text format     Related articles    Abstract available
     
     
     
109. HUANG WC , Havel JJ, Zhau HE, Qian WP, et al
     {beta}2-Microglobulin Signaling Blockade Inhibited Androgen Receptor Axis and Caused Apoptosis in Human Prostate Cancer Cells.
     Clin Cancer Res. 2008;14:5341-7.
     PubMed     Text format     Related articles    Abstract available
     
     
     
110. YANG W , Luo D, Wang S, Wang R, et al
     TMTP1, a novel tumor-homing peptide specifically targeting metastasis.
     Clin Cancer Res. 2008;14:5494-502.
     PubMed     Text format     Related articles    Abstract available
     
     
     August 2008
111. LECHLEIDER RJ , Arlen PM, Tsang KY, Steinberg SM, et al
     Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant.
     Clin Cancer Res. 2008;14:5284-91.
     PubMed     Text format     Related articles    Abstract available
     
     
     
112. PATEL H , Mick R, Finlay J, Zhu TC, et al
     Motexafin lutetium-photodynamic therapy of prostate cancer: short- and long-term effects on prostate-specific antigen.
     Clin Cancer Res. 2008;14:4869-76.
     PubMed     Text format     Related articles    Abstract available
     
     
     
113. HU Y , Dobi A, Sreenath T, Cook C, et al
     Delineation of TMPRSS2-ERG splice variants in prostate cancer.
     Clin Cancer Res. 2008;14:4719-25.
     PubMed     Text format     Related articles    Abstract available
     
     
     
114. SHARIFI N , Dahut WL, Figg WD
     The genetics of castration-resistant prostate cancer: what can the germline tell us?
     Clin Cancer Res. 2008;14:4691-3.
     PubMed     Text format     Related articles    Abstract available
     
     
     
115. SCHAUE D , Comin-Anduix B, Ribas A, Zhang L, et al
     T-cell responses to survivin in cancer patients undergoing radiation therapy.
     Clin Cancer Res. 2008;14:4883-90.
     PubMed     Text format     Related articles    Abstract available
     
     
     July 2008
116. CHAKRABORTY M , Wansley EK, Carrasquillo JA, Yu S, et al
     The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing.
     Clin Cancer Res. 2008;14:4241-9.
     PubMed     Text format     Related articles    Abstract available
     
     
     
117. GARDNER ER , Dahut WL, Scripture CD, Jones J, et al
     Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel.
     Clin Cancer Res. 2008;14:4200-5.
     PubMed     Text format     Related articles    Abstract available
     
     
     June 2008
118. GANESH S , Gonzalez-Edick M, Gibbons D, Van Roey M, et al
     Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models.
     Clin Cancer Res. 2008;14:3933-41.
     PubMed     Text format     Related articles    Abstract available
     
     
     
119. SHARIAT SF , Karam JA, Walz J, Roehrborn CG, et al
     Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers.
     Clin Cancer Res. 2008;14:3785-91.
     PubMed     Text format     Related articles    Abstract available
     
     
     
120. SARAMAKI OR , Harjula AE, Martikainen PM, Vessella RL, et al
     TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis.
     Clin Cancer Res. 2008;14:3395-400.
     PubMed     Text format     Related articles    Abstract available
     
     
     
121. MOSQUERA JM , Perner S, Genega EM, Sanda M, et al
     Characterization of TMPRSS2-ERG Fusion High-Grade Prostatic Intraepithelial Neoplasia and Potential Clinical Implications.
     Clin Cancer Res. 2008;14:3380-5.
     PubMed     Text format     Related articles    Abstract available
     
     
     
122. SVATEK RS , Karam JA, Roehrborn CG, Karakiewicz PI, et al
     Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy.
     Clin Cancer Res. 2008;14:3362-6.
     PubMed     Text format     Related articles    Abstract available
     
     
     
123. HAMADA A , Sissung T, Price DK, Danesi R, et al
     Effect of SLCO1B3 Haplotype on Testosterone Transport and Clinical Outcome in Caucasian Patients with Androgen-Independent Prostatic Cancer.
     Clin Cancer Res. 2008;14:3312-8.
     PubMed     Text format     Related articles    Abstract available
     
     
     
124. SFANOS KS , Bruno TC, Maris CH, Xu L, et al
     Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing.
     Clin Cancer Res. 2008;14:3254-61.
     PubMed     Text format     Related articles    Abstract available
     
     
     May 2008
125. RAINA K , Rajamanickam S, Singh RP, Agarwal R, et al
     Chemopreventive efficacy of inositol hexaphosphate against prostate tumor growth and progression in TRAMP mice.
     Clin Cancer Res. 2008;14:3177-84.
     PubMed     Text format     Related articles    Abstract available
     
     
     
126. WILLEMS AJ , Dawson SJ, Samaratunga H, De Luca A, et al
     Loss of heterozygosity at the BRCA2 locus detected by multiplex ligation-dependent probe amplification is common in prostate cancers from men with a germline BRCA2 mutation.
     Clin Cancer Res. 2008;14:2953-61.
     PubMed     Text format     Related articles    Abstract available
     
     
     
127. GOEL S , Cohen M, Comezoglu SN, Perrin L, et al
     The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development.
     Clin Cancer Res. 2008;14:2701-9.
     PubMed     Text format     Related articles    Abstract available
     
     

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: